Josep Sabaté, M.D.

Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS

Results are alligned w/ other MammaPrint High 2 results

@oncoalert.bsky.social

13.12.2024 15:56 — 👍 10    🔁 6    💬 0    📌 0

IBCC - International Breast Cancer Center on LinkedIn: #cáncerdemama #oncology #breastcancer #her2 #her2… Queridos Reyes Magos: Con el año recién estrenado y toda nuestra ilusión y esperanza puestas en la investigación para dar más y mejor vida a nuestr@s…

www.linkedin.com/posts/ibcc-i...

02.01.2025 19:19 — 👍 0    🔁 0    💬 0    📌 0

IBCC - International Breast Cancer Center on LinkedIn: #navidad #saludosnavideños #feliz2025 Todas las personas que formamos parte del IBCC os deseamos una Feliz Navidad y un Feliz Año Nuevo, en el que os seguiremos acompañando para afrontarlo, juntos,…

www.linkedin.com/posts/ibcc-i...

25.12.2024 11:18 — 👍 0    🔁 0    💬 0    📌 0

Anthracyclines still have a role in the treatment of those patients with early breast cancer at very high risk of disease recurrence!

13.12.2024 15:42 — 👍 6    🔁 3    💬 0    📌 1

#SABCS24 #bcsm #OncSky

🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social

12.12.2024 23:44 — 👍 18    🔁 7    💬 1    📌 0

AWESOME slide by Dr Michael Danso summing up his approach to HR+ MBC!! #SABCS24

13.12.2024 23:46 — 👍 9    🔁 6    💬 1    📌 0

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…

CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review

Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear

Read more👇
www.sciencedirect.com/science/arti...

#bcsm #BreastCancer

20.12.2024 07:50 — 👍 10    🔁 2    💬 0    📌 0

Dr. Bianchini describes the 🐘 in the room at #SABCS24.

❓Are PD-L1 and PD1 not created equal in breast?

🔑It is clear, neoadjuvant compared to adj immunotherapy should be given

⚠️ highlights ER low should be included in ICI trials

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

13.12.2024 16:51 — 👍 18    🔁 9    💬 0    📌 1

No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.)

For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.

13.12.2024 21:36 — 👍 28    🔁 8    💬 2    📌 0

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social

17.12.2024 14:30 — 👍 10    🔁 3    💬 1    📌 0

RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.

2nd line PFS >11 months with fulvestrant.

Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.

Hoping this one moves forward!

#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social

11.12.2024 21:42 — 👍 22    🔁 11    💬 2    📌 0

Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!

17.11.2024 23:03 — 👍 71    🔁 16    💬 3    📌 2